http://www.phrma.org/newmedicines/resources/bio00.pdf page 7
Corixa Corporation - news: Corixa files supplemental application for expanded use of BEXXAR Corixa files supplemental application for expanded use of BEXXAR 07/06/2004 SEATTLE, July 6, 2004 – Corixa Corporation (NASDAQ: CRXA), a developer of immunotherapeutics, today announced it has filed a supplemental Biologics License Application (BLA) on July 1, 2004 with the U.S.
Corixa Corporation - news: Corixa and GlaxoSmithKline Announce FDA Acceptance of Supplemental Biologics License Application for Corixa and GlaxoSmithKline Announce FDA Acceptance of Supplemental Biologics License Application for Expanded Use of BEXXAR FDA Response Expected by January 2005 09/20/2004 SEATTLE and PHILADELPHIA — Sept.
Corixa Corporation - news: Studies presented at ASH explore activity of the BEXXAR® therapeutic regimen in difficult-to-treat Studies presented at ASH explore activity of the BEXXAR® therapeutic regimen in difficult-to-treat lymphomas New Analysis Confirms Most Complete Remissions in Follicular non-Hodgkin’s Lymphoma Persist for Years Following Single Treatment with BEXXAR 12/08/2003 SAN DIEGO, CALIFORNIA, December 8, 2003 – Corixa Corporation (Nasdaq: CRXA) and GlaxoSmithKline (NYSE: GSK)...
Corixa Corporation - news: Corixa and GlaxoSmithKline announce results of two studies of BEXXAR® following chemotherapy as Corixa and GlaxoSmithKline announce results of two studies of BEXXAR® following chemotherapy as first-line treatment of non-Hodgkin's lymphoma presented at ASCO 06/07/2004 NEW ORLEANS, LOUISIANA, June 7, 2004 – Therapy with two different standard chemotherapeutic regimens, each followed by a single treatment with the BEXXAR® therapeutic regimen (Tositumomab and Iodine...
Corixa Corporation - news: Corixa and GlaxoSmithKline announce commercial availability of BEXXAR® therapeutic regimen Corixa and GlaxoSmithKline announce commercial availability of BEXXAR® therapeutic regimen 07/31/2003 SEATTLE and PHILADELPHIA, July 31, 2003 – Corixa Corp.
Corixa Corporation - news: Corixa and GlaxoSmithKline announce assignment of Medicare codes for the BEXXAR® therapeutic regimen Corixa and GlaxoSmithKline announce assignment of Medicare codes for the BEXXAR® therapeutic regimen 09/11/2003 SEATTLE and PHILADELPHIA, September 11, 2003 – Corixa Corp.
Corixa Corporation - news: BEXXAR® following chemotherapy produced a high rate of response as first-line treatment in patients BEXXAR ® following chemotherapy produced a high rate of response as first-line treatment in patients with follicular non-Hodgkin's lymphoma 09/22/2003 SEATTLE and PHILADELPHIA, September 22, 2003 – A novel therapeutic approach of BEXXAR ® (Tositumomab and Iodine I 131 Tositumomab) following chemotherapy has been shown to produce a high...
Corixa Corporation - news: Corixa and GlaxoSmithKline report progress on FDA review of BEXXAR® therapy application Corixa and GlaxoSmithKline report progress on FDA review of BEXXAR® therapy application 05/05/2003 SEATTLE and PHILADELPHIA, May 5, 2003 – Corixa Corporation (Nasdaq: CRXA) and GlaxoSmithKline (NYSE: GSK) today announced that many of the steps required for approval of BEXXAR® therapy (tositumomab and iodine I 131 tositumomab) are complete.
Corixa Corporation - news: Corixa and GlaxoSmithKline enter into a license and supply agreement for BEXXAR™ therapy in Canada Corixa and GlaxoSmithKline enter into a license and supply agreement for BEXXAR™ therapy in Canada 05/28/2003 SEATTLE, WA, and MISSISSAUGA, ON, May 28, 2003 – Corixa Corporation (Nasdaq: CRXA) and GlaxoSmithKline Inc.
Corixa Corporation - news: Corixa and GlaxoSmithKline announce analysis of long-term response population from BEXXAR clinical Corixa and GlaxoSmithKline announce analysis of long-term response population from BEXXAR clinical trials presented at ASCO 05/31/2003 Data Reported With Up To Nine Years of Follow-up CHICAGO, ILLINOIS, May 31, 2003 – According to data presented today at the 39th annual meeting of the American Society of Clinical Oncology (ASCO, Abstract #2316), a high proportion of patients...
Corixa Corporation - powering the immune system The U.S.BEXXAR ® (Tositumomab and Iodine I 131 Tositumomab) for the treatment of patients with CD20 positive, follicular, non-Hodgkin's lymphoma, with and without transformation, whose disease is refractory to Rituximab and has relapsed following chemotherapy.BEXXAR will be co-marketed in the...
Corixa Corporation - news: Corixa and GlaxoSmithKline announce FDA approval of BEXXAR®-br- -i-The BEXXAR® therapeutic regimen Corixa and GlaxoSmithKline announce FDA approval of BEXXAR® The BEXXAR® therapeutic regimen produced durable responses in patients with follicular non-Hodgkin’s lymphoma (NHL) whose disease had relapsed after chemotherapy and was refractory to rituximab 06/30/2003 SEATTLE and PHILADELPHIA, June 30, 2003 – Corixa Corporation (Nasdaq: CRXA) and GlaxoSmithKline (NYSE...
Corixa Corporation - news: The European Commission designates tositumomab and Iodine 131 radiolabelled tositumomab (BEXXAR The European Commission designates tositumomab and Iodine 131 radiolabelled tositumomab (BEXXAR therapy) as an orphan medicinal product 02/24/2003 Seattle, February 24, 2003 -- Corixa Corp.
Corixa Corporation - news: 2003 and Corixa Corporation sign research, development and license agreement Agreement to use SuperAntibody Technology for Corixa’s therapeutic antibody development program 09/08/2003 Corixa announces first approval of an infectious disease vaccine containing the company's RC-529™ adjuvant Berna Biotech’s SUPERVAX approved for sale in Argentina 09/02/2003 Corixa to present...
BIOPHARMA FDA Approvals - - - - BioNews BioWeb Companies Products BioReports - - - - - Channels Select Channel -------> Channels Home Page BioWeb Search BioNews Search BioNews Topics BioWatch Tracking BioJob Career Bio/Pharma Events BioNewsCast BioCorporate BioReports Indication/Disease BioZak CD-rom BioTechnologies BioExecutive BioEquities/Stocks BioDrug Discovery BioJournal BioAnalysis BioSuppliers...
Approved Products_2004.xls 194 Jul- 02 Aranes p hyperglycosylated erythropoietin Chemotherapy- induced anemia Amgen 195 Jul- 02 X yrem Sodium oxybate oral solution Cataplexy associated with narcolepsy Orphan Medical 196 Au g- 02 Prestara Prasterone Lupus Genelabs 197 Se p- 02 Hepsera Adefovir dipivoxil Chronic Hepatitus B Gilead 198 Nov- 02 Mitoz ytrex Generic mitomycin Disseminated adenocarcinoma of the...
author: Reijer
Approved Products_2004.xls page 5
author: Reijer
Database I See Bexxar ™ (2012) I2S (Iduronate-2-Sulfatase) (2936) I-PREX ™ (rBPI21) (1534) IAPP-Amyloid Fibrillogenesis Inhibitor (1843) Ibandronate.
Database B B - investigational drugs, therapies and vaccines # - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z From this page you may order documents with information covering investigational products.
http://www.corixa.com/2003AnnualReport_10k.pdf page 17
http://www.corixa.com/2003AnnualReport_10k.pdf page 16
http://www.corixa.com/2003AnnualReport_10k.pdf page 9
http://www.corixa.com/2003AnnualReport_10k.pdf page 4
http://www.corixa.com/2003AnnualReport_10k.pdf CHOP 1997 Rituxan 1998 BEXXAR 1999 FRANK'S DURATION OF RESPONSE (in years) TREATMENT DATE 1 2 34 BEXXAR therapeutic regimen pairs the targeting ability of a monoclonal antibody (Tositumomab) and the therapeutic potential of radiation (Iodine - 131) with patient- specific dosing.
